Saturday, January 23, 2021

Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

- Ad -“bathbybex

SEATTLE–(BUSINESS WIRE)–Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the closing of its previously announced initial public offering of 13,225,000 shares of its common stock, which includes 1,725,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $21.00 per share. Including the option exercise, the aggregate gross proceeds to Silverback from the offering were approximately $277.7 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading on the Nasdaq Global Market on December 4, 2020, under the ticker symbol “SBTX.”

RELATED:  Sir Andrew Witty Returns to UnitedHealth Group After Leave of Absence

Goldman Sachs & Co. LLC, SVB Leerink and Stifel acted as joint book-running managers for the offering. H.C. Wainwright & Co. acted as the lead manager for the offering.

RELATED:  bioMérieux Launches Predictive Diagnostics, Pairing Microbiology Solutions With Data Science, Sequencing and Predictive Modeling

Registration statements relating to these securities have been filed with the Securities and Exchange Commission (SEC) and became effective on December 3, 2020. Copies of the registration statements can be accessed through the SEC’s website at This offering was made only by means of a written prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the initial public offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, or by telephone at (866) 471-2526, or by email at [email protected]; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at (800) 808-7525, ext. 6132, or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, or by telephone at (415) 364-2720, or by email at [email protected].

RELATED:  The Container Store Group, Inc. Announces Second Quarter Fiscal 2020 Financial Results
RELATED:  HistoGenetics Expands Service Offerings and Capacity to Deliver More Complete Genomic Information

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

- Ad -magicalbutter


Steve E. Kunszabo

Canale Communications

(619) 849-5392

[email protected]

- Ad -CBD Living

What Others are Reading:

How to Make Cannabis Gummies in 9 Easy Steps

Love cannabis gummies? @MagicalButter brings to Ganjly their recipe on how to make cannabis gummies.  Skill Level: Easy Prep Time: 10 minutes Cook Time: 2 hours Serving...

How to Make Cannabis Infused Butter in 3 Easy Steps